Pneumonitis: Diagnostic Workup and Treatment
For immune-related pneumonitis, immediately interrupt immunotherapy for grade 1-2 disease and start prednisone 1-2 mg/kg orally, while permanently discontinuing immunotherapy and hospitalizing patients with grade 3-4 disease for high-dose IV methylprednisolone 2-4 mg/kg. 1
Diagnostic Workup
Initial Assessment
- Obtain CT chest with contrast to evaluate pulmonary parenchymal opacities, typically showing ground-glass opacities, cryptogenic organizing pneumonia-like patterns, or interstitial pneumonia patterns in bilateral nonsegmental distribution 1, 2
- Rule out infection immediately through comprehensive infectious workup including nasal swab, sputum culture, blood cultures, urine cultures, and COVID-19 testing for grade 2 or higher pneumonitis 3, 1
- Perform pulse oximetry to assess oxygenation status 3
Bronchoscopy Considerations
- Bronchoscopy with bronchoalveolar lavage is recommended for symptomatic pneumonitis to identify infections, including opportunistic or atypical agents, especially before initiating immunosuppression in grade 2 disease 1
- Lung biopsy is generally not required for management but may assist when radiological or clinical doubt exists regarding etiology, particularly to exclude infection, lymphangitic spread, or other inflammatory processes 1
- Transbronchial biopsy has limited utility while patients are on antibiotics due to high false-negative rates 4
Temporal and Exposure Assessment
- Document temporal relationship between drug exposure and symptom onset, with median time to onset of 2.8 months for immune checkpoint inhibitors (range 9 days to 19.2 months) 1
- Elicit detailed occupational and environmental exposure history including animal exposures, travel history, and potential hypersensitivity triggers 4, 5, 6
Treatment Algorithm
Grade 1-2 Pneumonitis (Mild to Moderate)
- Interrupt immune checkpoint inhibitor therapy 1
- Start prednisone 1-2 mg/kg orally 1
- Assess clinically every 2-3 days initially, with radiological reassessment for grade 2 disease 1
- Taper steroids over 4-6 weeks after recovery 1
- Delay checkpoint inhibitor reintroduction until daily prednisone dose ≤10 mg 1
- Consider broad-spectrum antibiotics if infectious status cannot be reliably assessed 1
Grade 3-4 Pneumonitis (Severe to Life-Threatening)
- Permanently discontinue immune checkpoint inhibitor 1
- Hospitalize immediately, including ICU admission if necessary 1
- Initiate high-dose IV methylprednisolone 2-4 mg/kg/day 1
- Add second-line immunosuppression if no improvement within 48 hours: infliximab, mycophenolate mofetil (1000 mg three times daily), or cyclophosphamide 1, 3, 1
- Administer broad-spectrum antibiotics in parallel with immunosuppression when infectious status uncertain 1
- Taper steroids very slowly over 6 weeks or more due to risk of relapse during tapering 1
Critical Pitfalls
Diagnostic Challenges
- Radiological features are not pathognomonic and can mimic disease progression, particularly in lung cancer patients with metastases 1
- Pneumonitis occurs later than other immune-related adverse events, typically months after treatment initiation, requiring sustained vigilance 1
- Treatment-related deaths are higher in NSCLC patients despite similar grade 3-4 rates across tumor types 1
Management Considerations
- Combination immunotherapy (anti-PD-1/PD-L1 plus anti-CTLA4) increases pneumonitis risk 3-fold compared to monotherapy (10% vs 3%) 1
- Steroid-refractory pneumonitis requires prompt escalation to additional immunosuppression rather than continued high-dose steroids alone 3, 1
- Relapses during steroid tapering are documented, necessitating slow, careful tapering over extended periods 1